Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Stopped Per CTEP, Martha Khrum this study is withdrawn. Changing status to update CT.gov

Conditions

• Recurrent Plasma Cell Myeloma
• Refractory Plasma Cell Myeloma
• t(11;14) Negative

Interventions

• DRUG: Dexamethasone
• DRUG: Ixazomib
• DRUG: Ixazomib Citrate
• DRUG: Venetoclax

Sponsor

National Cancer Institute (NCI)